Comparing this to SRX is just plain wrong. And your statements about SRX relying on a supplementary use of their technology is INCORRECT.
To assist you, SRX is making money because they are supplying end of the line therapy. The latest announcement just means that the treatment is not suitable for first line therapy. Their technology has never been for a supplementary use, as all their revenue is derived from the primary use as end of line therapy.
If you need to ask what the above means, then you dont know enough, and should not comment on something you are ignorant on.
fundamental msb (no chart talk), page-7
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |